TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Tarsons Products Limited
TARSONS

Tarsons Products Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 46/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹332.75

Change

-2.7 (-0.8%)

Open

₹341.0

Prev. Close

₹335.45

Day High

₹345.0

Day Low

₹327.45

Volume Analysis

Traded

97,118

Delivered

36,808

Delivery %

37.9%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (27.0%)

Weaknesses (2)

  • •Low return on equity (2.44%)
  • •Below-average fundamentals quality score (46/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹360.24 ₹352.62 ₹342.69 ₹335.07 ₹325.14 ₹317.52 ₹307.59
Fibonacci ₹352.62 ₹345.92 ₹341.77 ₹335.07 ₹328.37 ₹324.22 ₹317.52
Camarilla ₹337.58 ₹335.97 ₹334.36 ₹335.07 ₹331.14 ₹329.53 ₹327.92

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+41.72%

1 Week

-2.51%

1 Month

+0.15%

3 Months

+24.17%

6 Months

+84.98%

1 Year

+8.3%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹84.87

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

1.68%

Net margin 2.49% × asset turnover 0.36x × equity multiplier 1.87x

Company Overview

Sector

Healthcare

Market Cap

₹1,770 Cr

P/E (TTM)

150.0

ROE

2.44%

Book Value

₹119.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Tarsons Products Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 46/100. The strongest factor is Financial Strength (81/100), while Institutional Ownership (10/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%); low return on equity (2.44%); below-average fundamentals quality score (46/100). FII holding has been falling.

TopFund Score — Fundamentals Quality

46/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

81

Growth

30

Valuation

25

Cash Flow

50

Corporate Governance

56

Momentum

80

Institutional Ownership

10

Business Quality

48

Risk & Volatility

38

Liquidity

25

From Screener.in

  • −Stock is trading at 2.79 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of 4.68% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Closure of Trading Window 24 Sep

Trading window closes from October 1, 2026 until 48 hours after Q2 FY27 results.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Sep 24 Sep
Shareholder Meeting / Postal Ballot-Outcome of AGM 24 Sep 24 Sep
Response On Clarification Sought On Spurt In Volume Of Tarsons Products Limited 22 Sep

Tarsons clarifies September 22, 2026 volume spurt; no undisclosed material information exists.

Clarification sought from Tarsons Products Ltd 22 Sep

Exchange has sought clarification from Tarsons Products Ltd on September 22, 2026, with reference to Movement in Volume.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2021 Mar 2022 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 71 85 62 106 85 99 96 113 91 102 108 121 110
Expenses + 38 41 39 75 66 74 66 76 67 75 76 87 84
Operating Profit 33 44 23 30 19 25 30 37 25 27 32 34 26
OPM % 46.9% 52.19% 37.03% 28.6% 22.12% 25.5% 30.98% 32.85% 27.04% 26.82% 29.21% 28.34% 23.58%
Other Income + 2 3 3 3 3 8 1 4 3 6 7 7 6
Interest 1 0 3 4 4 5 5 5 5 5 6 6 6
Depreciation 5 7 10 12 11 14 17 20 20 22 25 29 27
Profit before tax 29 39 14 17 6 15 8 16 3 6 8 6 -1
Tax % 25.66% 24.89% 26.72% 39.5% 36.39% 30.8% 34.66% 34.49% 41.25% 40.61% 32.93% 27.56% 9.09%
Net Profit + 21 29 10 10 4 10 5 10 2 3 5 4 -1
EPS in Rs 4 6 2 2 1 2 1 2 0 1 1 1 0
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 229 301 296 392 423 441
Expenses + 125 148 196 282 304 322
Operating Profit 103 153 100 111 118 119
OPM % 45.0% 51.0% 34.0% 28.0% 28.0% 27.0%
Other Income + 5 8 11 16 23 26
Interest 3 4 10 20 23 24
Depreciation 14 22 40 62 97 104
Profit before tax 92 135 61 45 22 18
Tax % 25.0% 25.0% 30.0% 34.0% 35.0% —
Net Profit + 69 101 43 30 14 11
EPS in Rs 3,583 19 8 6 3 2
Dividend Payout % 0.0% 0.0% 25.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Reserves 244 479 602 620 624
Borrowings + 34 22 269 339 393
Other Liabilities + 18 33 90 111 158
Total Liabilities 296 544 972 1,080 1,186
Fixed Assets + 120 189 336 536 733
CWIP 22 32 267 233 159
Investments 0 0 0 0 0
Other Assets + 153 323 369 311 295
Total Assets 296 544 972 1,080 1,186
Equity Capital 0 11 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 68 83 103 114 118
Cash from Investing Activity + -64 -138 -285 -145 -129
Cash from Financing Activity + -27 130 136 39 9
Net Cash Flow -23 75 -47 8 -2
CFO/OP 89 77 121 117 107
Free Cash Flow 6 -48 -81 -37 -7

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 47.31% → 47.3%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 41.68% 43.27% 44.36% 44.63% 44.45% 44.69% 42.89% 43.5% 46.79% 50.23% 51.65% 52.44%
Promoters 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.31% 47.3% 47.3% 47.3%
FII 7.85% 6.83% 8.16% 7.95% 8.04% 7.51% 9.53% 9.14% 5.82% 2.46% 0.87% 0.15%
DII 3.15% 2.6% 0.17% 0.11% 0.21% 0.51% 0.3% 0.04% 0.08% 0.0% 0.19% 0.1%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Tarsons Products Limited (this stock) 1,770 150.0 2.8 2.44%
Krsnaa Diagnostics Ltd 1,785 18.3 1.81 10.9%
Suraksha Diagnostic Ltd 1,788 49.9 7.3 14.2%
Ngl Fine Chem Limited 1,796 31.4 5.45 17.4%
Hester Biosciences Ltd 1,884 35.5 5.24 15.9%
Syncom Formu (i) Ltd 1,885 22.0 4.54 17.6%
Anlon Healthcare Limited 1,655 52.3 7.18 18.4%

Which Mutual Funds Hold Tarsons Products Limited?

Frequently Asked Questions about Tarsons Products Limited

Community Sentiment

What are other investors saying about Tarsons Products Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.